Navigation Links
New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes

rching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2006, Boehringer Ingelheim posted net sales of 10.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit http://www.boehringer-ingelheim.com

Please be advised

This release is from the Corporate Headquarters of Boehringer Ingelheim and is intended for all international markets. This being the case, please be aware that there may be some differences between countries regarding specific medical information including licensed uses. Please take account of this when referring to the material.

<< References

(1) Burgess E et al. Efficacy of telmisartan compared with losartan in reducing proteinuria in hypertensive type 2 diabetic patients with overt nephropathy. Presented at the Annual Meeting of the European Society of Hypertension. June 2007, Milan, Italy.

(2) Hossain P et al. Obesity and Diabetes in the Developing World - a Growing Challenge. NEJM 2007; 356(3):213-215.

(3) Wild S et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047- 53.

(4) US Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Available at: http://www.usrds.org/atlas.htm">http://www.usrds.org/atlas.htm. Accessed 06-2007.

(5) Yue JL et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Ne
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/9/2008)...O, May 9 /- Ardea Bioscienc...e discovery and development of,small- molecule the...lammatory diseases, including gout, today announce... President, Finance and Operations and Chief,Finan...n from our board of,directors shortly thereafter. ...
(Date:5/8/2008)...Largest Renal Research Network Completes 13 Phase-...als in Late Stage Development, EL SEGUNDO, Calif....),(DCR), a Phase I-IV clinical trial research serv...d device research and development for FDA approval...in 2007 and has another 34,active trials in late s...
(Date:5/8/2008)...May 8 /- The Cancer Research Alliance...top cancer centers, is asking,303 million American...$1 to,cancer research efforts this Mother,s Day th...finite Power of One(TM)" has two key goals:,to act...eir own hands by,joining together to exercise thei...
(Date:5/8/2008)...la., May 8 /- Alpharma Inc....company, today announced results from,clinical tri...ate,extended-release with sequestered naltrexone h...evant features addressing abuse liability,alongsid...se I and II,studies, presented at the 27th Annual ...
Breaking Medicine Technology:Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6DaVita Clinical Research Completes Record Number of Renal Trials in 2007 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 4World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 2Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 3Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 4Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 6Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 7Simons Foundation awards Emory scientists 243M for autism gene research 674 1Simons Foundation awards Emory scientists 243M for autism gene research 674 2Energizer Joins Roster of Susan G Komen Race for the Cure 28R 29 National Sponsors 3B Energizer 28R 29 ReTreat Pampers Cancer Survivors With Travelin 2870 1Energizer Joins Roster of Susan G Komen Race for the Cure 28R 29 National Sponsors 3B Energizer 28R 29 ReTreat Pampers Cancer Survivors With Travelin 2870 2Energizer Joins Roster of Susan G Komen Race for the Cure 28R 29 National Sponsors 3B Energizer 28R 29 ReTreat Pampers Cancer Survivors With Travelin 2870 3Phlo Affiliate Hires Chief Marketing Officer With Extensive Global Experience 1058 1Phlo Affiliate Hires Chief Marketing Officer With Extensive Global Experience 1058 2Nestle Nutrition and Phosphagenics to Commence Phospha E 28R 29 Phase 2 Clinical Trial 447 1Nestle Nutrition and Phosphagenics to Commence Phospha E 28R 29 Phase 2 Clinical Trial 447 2Nestle Nutrition and Phosphagenics to Commence Phospha E 28R 29 Phase 2 Clinical Trial 447 3Nestle Nutrition and Phosphagenics to Commence Phospha E 28R 29 Phase 2 Clinical Trial 447 4
...April 18, 2007 /PRNewswire/ -- Micell,Technologies...ng,data on use of its supercritical fluid (SCF) su...nts at the upcoming Society for,Biomaterials 2007 ...ois. , The abstracts describe use of Micell and PN...logy to create drug-eluting stents,containing crys...
...d. and CARLSBAD, Calif., April 18, 2007,/PRNewswir... today,announced data from a preclinical study in ... antigen (CEA) were shown to prevent,subcutaneous ...established marker for tumor progression, CEA is f...an carcinomas. These data,presented yesterday in ...
Other Medicine Technology:Micell Technologies Presents Data on Novel Drug-Eluting Stents 2Micell Technologies Presents Data on Novel Drug-Eluting Stents 3Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 2Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 3Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 4Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 5
(Date:5/11/2008)...ers of today,s Susan G.,Komen Pittsburgh Race for ...Winners Male: Pat McGuire, Charlottesville, ...urgh, Pa., 19:19, 2nd Place Overall Winners ..., Washington, Pa., 19:22, 3rd Place Overall Winne... Female: Jessica Winter, Pittsburgh, Pa., 19...
(Date:5/11/2008)...ling of the New Name of the Nation,s...11 /PRNewswire/ -- Thousands of people honoring Mo...esent for the unveiling of the,new name and logo o...anization, This year, Y-ME National Breast Cancer...y. In celebration of this landmark, Y-ME revealed ...
(Date:5/10/2008)... Clearance for Airlift of ...ewswire-USNewswire/ -- An AmeriCares,emergency rel...ess the,crisis situation and continue with efforts...t of 15 tons of essential medicines and medical,su... with the World Health Organization to,help coordi...
(Date:5/9/2008).../ -- AMDL, Inc. (Amex: ADL ),an international ve...ny,with operations in China through its wholly own...ounced that its consolidated financial,statements ...ncluded in its,Annual Report on Form 10-K filed wi... 14, 2008, contained a ,going concern, qualificati...
Breaking Medicine News(10 mins):Health News:16th Annual Komen Pittsburgh Race for the Cure(R) Winners Announced 2Health News:Y-ME Makes Historic Announcement on Mother's Day 2Health News:Y-ME Makes Historic Announcement on Mother's Day 3Health News:AmeriCares Relief Worker Arrives in Myanmar 2Health News:AMDL Reports Going Concern Qualification 2
...e world vehemently oppose wastage of food. They ne...ies have children who are starving. //However Euro... published reports about Canadians who take the ef...terally daub food on their bodies as well. Trendy ...
...ood' – The general belief of so many is confirmed ...nd study confirms // that the concept of eating sl...infact was bandied about for decades due to the la...rovides a direct relation between slow eating and ...
...spected a connection between chronic lung diseases...has yielded widely varying estimates about the str...es have used different diagnosis criteria for thes...hers presented preliminary data at the American Co...
...ersity School of Medicine suggests that certain in...icals our bodies produce during times of high stre... failure and lupus that involve inflammation. The ...h.D., and Matthew Loza, Ph.D, found that beta-agon...
Other Medicine News:Health News:Tasty Cosmetic Recipes to flavor your day 2Health News:Study Examines Link Between Rheumatoid Arthritis and Chronic Lung Diseases 2Health News:Beta Agonists May Alter the Immune System 2
Delivers the durability of natural tissue with all the corresponding benefits of ingrowth and natural adaptation to surrounding tissues. Meets or exceeds all applicable state and federal tissue guide
...ned specifically for rehabilitation facilities. Th...ock absorbing deck that provides the ideal cushion...-friendly control panel displays all pertinent inf...eadmills features a "soft start" the belt starts ...
The Q-Tel RMS system is a state-of-the-art, comprehensive cardiac monitoring and data management system. Its programs, modalities, and parameters are highly customizable and lend outstanding support
...OCARE) Bladder System is a medical device which ha... empty their bladder (or urinate) on demand. A sec...tion and promote penile erection.,The Bladder Syst...ts, and an external control unit. Internally, a pa...
Medicine Products: